Systemic Mastocytosis is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Systemic Mastocytosis have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Systemic Mastocytosis compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Systemic Mastocytosis overview
Systemic mastocytosis is a disorder where mast cells are abnormally increased in multiple organs including the bone marrow. Symptoms include shortness of breath, low blood pressure, hives and swelling, itching, diarrhea, headache, flushing, and musculoskeletal pain. Treatment includes antihistamines and more aggressive forms of medication, including interferon or chemotherapeutic agents.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Systemic Mastocytosis, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.